Advanced therapies for congenital heart disease: Ventricular assist devices and heart transplantation

Canadian Journal of Cardiology

Volumn 29, Issue 7, 2013, Pages 796-802

  VanderPluym, Christina ^a   Urschel, Simon ^b   Buchholz, Holger ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONGENITAL HEART DISEASE; DUCHENNE MUSCULAR DYSTROPHY; HEALTH CARE QUALITY; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HLA SYSTEM; HUMAN; MORTALITY; PREOPERATIVE EVALUATION; QUALITY OF LIFE; REVIEW; SENSITIZATION; SURVIVAL; THROMBOCYTE TRANSFUSION; VENTRICULAR ASSIST DEVICE;

CHILD; FONTAN PROCEDURE; HEART DEFECTS, CONGENITAL; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HLA ANTIGENS; HUMANS;

EID: 84879503693     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.02.008     Document Type: Review

References (54)

1. Kirk R., Dipchand A.I., Edwards L.B., et al. The registry of the International Society for Heart and Lung Transplantation: fifteenth pediatric heart transplantation report-2012. JHeart Lung Transplant 2012, 31:1065-1072.
2. Bernstein D., Naftel D., Chin C., et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation 2006, 114:273-280.
3. Michielon G., Parisi F., Squitieri C., et al. Orthotopic heart transplantation for congenital heart disease: an alternative for high-risk Fontan candidates?. Circulation 2003, 108(suppl 1):II140-II149.
4. De Robertis F., Birks E.J., Rogers P., Dreyfus G., Pepper J.R., Khaghani A. Clinical performance with the Levitronix Centrimag short-term ventricular assist device. JHeart Lung Transplant 2006, 25:181-186.
5. De Robertis F., Rogers P., Amrani M., et al. Bridge to decision using the Levitronix Centrimag short-term ventricular assist device. JHeart Lung Transplant 2008, 27:474-478.
6. Santise G., Petrou M., Pepper J.R., Dreyfus G., Khaghani A., Birks E.J. Levitronix as a short-term salvage treatment for primary graft failure after heart transplantation. JHeart Lung Transplant 2006, 25:495-498.
7. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan E.J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. JHeart Transplant 1990, 9:526-537.
8. Pauwaa S., Bhat G., Tatooles A.J., et al. How effective are continuous flow left ventricular assist devices in lowering high pulmonary artery pressures in heart transplant candidates?. Cardiol J 2012, 19:153-158.
9. Hetzer R., Alexi-Meskishvili V., Weng Y., et al. Mechanical cardiac support in the young with the Berlin Heart EXCOR pulsatile ventricular assist device: 15 years' experience. Seminars in thoracic and cardiovascular surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2006, 99-108.
10. Blume E.D., Naftel D.C., Bastardi H.J., Duncan B.W., Kirklin J.K., Webber S.A. Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study. Circulation 2006, 113:2313-2319.
11. Morales D.L., Almond C.S., Jaquiss R.D., et al. Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device. JHeart Lung Transplant 2011, 30:1-8.
12. Fraser C.D., Jaquiss R.D., Rosenthal D.N., et al. Prospective trial of a pediatric ventricular assist device. NEngl J Med 2012, 367:532-541.
13. Kirshbom P.M., Bridges N.D., Myung R.J., Gaynor J.W., Clark B.J., Spray T.L. Use of extracorporeal membrane oxygenation in pediatric thoracic organ transplantation. JThorac Cardiovasc Surg 2002, 123:130-136.
14. Chen J.M., Richmond M.E., Charette K., et al. Adecade of pediatric mechanical circulatory support before and after cardiac transplantation. JThorac Cardiovasc Surg 2012, 143:344-351.
15. VanderPluym C.J., Rebeyka I.M., Ross D.B., Buchholz H. The use of ventricular assist devices in pediatric patients with univentricular hearts. JThorac Cardiovasc Surg 2011, 141:588-590.
16. Everitt M.D., Donaldson A.E., Stehlik J., et al. Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). JHeart Lung Transplant 2011, 30:395-401.
17. Rose E.A., Moskowitz A.J., Packer M., et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg 1999, 67:723-730.
18. Lietz K., Long J.W., Kfoury A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-rematch era: implications for patient selection. Circulation 2007, 116:497-505.
19. Slaughter M.S. Destination therapy: the future is arriving. Congest Heart Fail 2005, 11:155-156.
20. Brancaccio G., Filippelli S., Michielon G., et al. Ventricular assist devices as a bridge to heart transplantation or as destination therapy in pediatric patients. Transplant Proc 2012, 44:2007-2012.
21. Hsu D.T., Lamour J.M., Canter C.E. Heart diseases leading to pediatric heart transplantation: cardiomyopathies and congenital heart diseases. International Society for Heart and Lung Transplantation. Monograph vol. 2: Pediatric Heart Transplantation 2007, 1-17. Elsevier, Philadelphia. C.E. Canter, J.K. Kirklin (Eds.).
22. Griffiths E.R., Kaza A.K., Wyler von Ballmoos M.C., et al. Evaluating failing Fontans for heart transplantation: predictors of death. Ann Thorac Surg 2009, 88:558-563. [discussion: 563-4].
23. Jayakumar K.A., Addonizio L.J., Kichuk-Chrisant M.R., et al. Cardiac transplantation after the Fontan or Glenn procedure. JAm Coll Cardiol 2004, 44:2065-2072.
24. Opelz G., Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. NEngl J Med 1994, 330:816-819.
25. Opelz G., Wujciak T., Dohler B., Scherer S., Mytilineos J. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999, 1:334-342.
26. Merrill J.P., Murray J.E., Harrison J.H., Guild W.R. Successful homotransplantation of the human kidney between identical twins. JAm Med Assoc 1956, 160:277-282.
27. Murray J.E., Merrill J.P., Harrison J.H. Kidney transplantation between seven pairs of identical twins. Ann Surg 1958, 148:343-359.
28. Lavee J., Kormos R.L., Duquesnoy R.J., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. JHeart Lung Transplant 1991, 10:921-929. [discussion: 929-30].
29. Stastny P., Lavingia B., Fixler D.E., Yancy C.W., Ring W.S. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007, 84:738-745.
30. Jacobs J.P., Quintessenza J.A., Boucek R.J., et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004, 78:1703-1709.
31. Mahle W.T., Tresler M.A., Edens R.E., et al. Allosensitization and outcomes in pediatric heart transplantation. JHeart Lung Transplant 2011, 30:1221-1227.
32. Ginevri F., Nocera A., Comoli P., et al. Posttransplant de novo donor-specific HLA antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant 2012, 12:3355-3362.
33. Urschel S., Campbell P.M., Meyer S.R., et al. Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age?. Am J Transplant 2010, 10:149-156.
34. Slichter S.J. Platelet refractoriness and alloimmunization. Leukemia 1998, 12(suppl 1):S51-S53.
35. Grijzenhout M.A., Aarts-Riemens M.I., de Gruijl F.R., van Weelden H., van Prooijen H.C. UVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994, 84:3524-3531.
36. Yang J., Schall C., Smith D., et al. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of luminex. JHeart Lung Transplant 2009, 28:123-129.
37. O'Connor M.J., Menteer J., Chrisant M.R., et al. Ventricular assist device-associated anti-human leukocyte antigen antibody sensitization in pediatric patients bridged to heart transplantation. JHeart Lung Transplant 2010, 29:109-116.
38. Baran D.A., Gass A.L., Galin I.D., et al. Lack of sensitization and equivalent post-transplant outcomes with the novacor left ventricular assist device. JHeart Lung Transplant 2005, 24:1886-1890.
39. John R., Pagani F.D., Naka Y., et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. JThorac Cardiovasc Surg 2010, 140:174-181.
40. George I., Colley P., Russo M.J., et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. JThorac Cardiovasc Surg 2008, 135:1372-1379.
41. Meyer S.R., Campbell P.M., Rutledge J.M., et al. Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg 2005, 27:554-560.
42. Laing B.J., Ross D.B., Meyer S.R., et al. Glutaraldehyde treatment of allograft tissue decreases allosensitization after the norwood procedure. JThorac Cardiovasc Surg 2010, 139:1402-1408.
43. Meyer S.R., Ross D.B., Forbes K., et al. Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery. JThorac Cardiovasc Surg 2007, 133:1517-1523.
44. Susskind B., Kerman R.H., Nelson R., et al. Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies. Transplantation 1998, 66:1823-1826.
45. Worthington J.E., Robson A.J., Sheldon S., Langton A., Martin S. Acomparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001, 62:1178-1184.
46. Minucci P.B., Grimaldi V., Casamassimi A., et al. Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. Exp Clin Transplant 2011, 9:381-386.
47. Zachary A.A., Vega R.M., Lucas D.P., Leffell M.S. HLA antibody detection and characterization by solid phase immunoassays: methods and pitfalls. Methods Mol Biol 2012, 882:289-308.
48. Ellis T.M., Schiller J.J., Roza A.M., Cronin D.C., Shames B.D., Johnson C.P. Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol 2012, 73:706-710.
49. West L.J. Toward donor allocation equitability for high immunological risk patients awaiting transplantation: "4S 4 HI-cPRA". Can J Cardiol 2011, 27:677-678.
50. Pollock-BarZiv S.M., den Hollander N., Ngan B.Y., et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007, 116:I172-I178.
51. Morrow W.R., Frazier E.A., Mahle W.T., et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 2012, 93:319-324.
52. Patel J., Everly M., Chang D., Kittleson M., Reed E., Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. JHeart Lung Transplant 2011, 30:1320-1326.
53. Schumacher K.R., Ramon D.S., Kamoun M., Caruthers R., Gajarski R.J. HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIG. JHeart Lung Transplant 2012, 31:1041-1042.
54. Medoff Cooper B., Holditch-Davis D., Verklan M.T., et al. Newborn clinical outcomes of the AWHONN late preterm infant research-based practice project. JObstet Gynecol Neonatal Nurs 2012, 41:774-785.